Sleeve gastrectomy and Roux-en-Y gastric bypass are the two most widely performed bariatric procedures in the UK, yet they differ meaningfully in how they work, their risk profiles, and their long-term outcomes. Understanding these differences is essential for anyone considering weight loss surgery through the NHS or privately. This article compares both procedures across mechanism, effectiveness, safety, eligibility, recovery, and the factors that guide surgical selection — drawing on current NICE guidance, BOMSS standards, and the best available clinical evidence to help patients and clinicians make informed decisions.

How Sleeve Gastrectomy and Roux-en-Y Gastric Bypass Work

Sleeve gastrectomy restricts stomach volume and reduces ghrelin, while Roux-en-Y gastric bypass creates a small pouch and reroutes the bowel, triggering pronounced GLP-1 and PYY hormonal responses that improve satiety and glycaemic control.

Have any more questions about this? Message our pharmaceutical team to get more info →

Sleeve gastrectomy and Roux-en-Y gastric bypass (RYGB) are the two most commonly performed bariatric surgical procedures in the UK. Both are offered through NHS specialist weight management services and aim to achieve sustained weight loss in people with obesity, but they work through distinct mechanisms.

Sleeve gastrectomy is predominantly restrictive but also produces important hormonal and metabolic effects. Approximately 75–80% of the stomach is surgically removed, leaving a narrow, sleeve-shaped tube that significantly reduces stomach capacity and limits food intake. Removal of the gastric fundus reduces circulating ghrelin — a hunger-stimulating hormone — and also influences GLP-1, peptide YY (PYY), bile acid signalling, and gastric emptying, all of which contribute to appetite suppression and metabolic improvement beyond simple restriction.

Roux-en-Y gastric bypass is best described as restrictive and metabolic, with only modest nutrient malabsorption in standard configurations (unlike more extensive procedures such as biliopancreatic diversion). A small gastric pouch (roughly 15–30 ml) is created from the upper stomach and connected directly to a section of the small intestine, bypassing the remainder of the stomach and the proximal small bowel. This rerouting triggers pronounced hormonal changes — including markedly enhanced release of GLP-1 and PYY — which improve satiety and glycaemic control. Caloric and nutrient absorption is reduced, but the dominant mechanisms are hormonal and metabolic rather than purely malabsorptive.

Both procedures are performed laparoscopically in most cases, reducing recovery time and surgical risk compared with open surgery. The choice between them depends on individual clinical factors, patient preference, and the expertise available at the treating centre. NHS and BOMSS patient information resources provide further detail on how each procedure works in practice.

Comparing Weight Loss Outcomes and Long-Term Effectiveness

Gastric bypass achieves approximately 25–30% total weight loss at five years versus 20–25% for sleeve gastrectomy, with superior long-term metabolic outcomes, particularly for type 2 diabetes remission.

Both procedures produce substantial and clinically meaningful weight loss, but the evidence consistently shows differences in magnitude and durability. Understanding these distinctions is important when weighing up the options.

In UK clinical practice, outcomes are increasingly reported as percentage of total weight loss (%TWL) rather than percentage of excess weight loss (%EWL), as %TWL is considered more consistent and is used in National Bariatric Surgical Registry (NBSR) reporting.

Roux-en-Y gastric bypass typically achieves greater weight loss:

• Approximately 25–30% TWL at five years in UK cohorts, though results vary by centre, baseline BMI, and patient factors

• More pronounced improvements in type 2 diabetes, with remission rates that are higher than sleeve gastrectomy in the short to medium term; however, remission rates decline over time and long-term data should be interpreted with caution

• Greater reductions in blood pressure, dyslipidaemia, and obstructive sleep apnoea

Sleeve gastrectomy also delivers significant results:

• Approximately 20–25% TWL at five years in UK cohorts

• Comparable short-term outcomes to bypass in many patients

• Some evidence of greater weight regain at 10 years; long-term data from randomised trials (including the SLEEVEPASS and SM-BOSS trials) continue to emerge

Randomised controlled trial data and meta-analyses published in Lancet Diabetes & Endocrinology confirm that RYGB produces superior long-term weight loss and metabolic outcomes compared with sleeve gastrectomy, particularly in patients with type 2 diabetes or severe obesity. However, the absolute difference in outcomes narrows in patients with lower BMI ranges within the surgical threshold.

Neither procedure is a guaranteed solution. Long-term success depends heavily on adherence to dietary guidance, physical activity, and ongoing psychological support. Both procedures can result in weight regain if lifestyle changes are not maintained, and patients should be counselled accordingly before surgery.

Risks, Complications, and Safety Considerations

Sleeve gastrectomy carries risks of staple line leak and worsening GORD; gastric bypass adds risks of dumping syndrome, post-bariatric hypoglycaemia, marginal ulceration, and greater nutritional deficiencies requiring lifelong monitoring.

As with all major surgical procedures, both sleeve gastrectomy and Roux-en-Y gastric bypass carry risks. These should be discussed thoroughly during the pre-operative assessment process, in line with NICE guidance (CG189, updated 2022).

General surgical risks applicable to both procedures include:

• Venous thromboembolism (VTE)

• Wound infection or port-site complications

• Anaesthetic complications

• Bleeding or haematoma formation

• Gallstone formation due to rapid weight loss; ursodeoxycholic acid prophylaxis may be considered in the early post-operative period

Sleeve gastrectomy-specific risks include:

• Staple line leak — a serious but uncommon complication; rates vary by centre and surgical experience, with UK data suggesting approximately 1–2% or lower at experienced centres

• Gastro-oesophageal reflux disease (GORD), which may worsen or develop post-operatively; this is a significant consideration for patients with pre-existing reflux or Barrett's oesophagus

• Stricture formation along the sleeve

Roux-en-Y gastric bypass-specific risks include:

• Anastomotic leak at the gastrojejunal join — uncommon but serious

• Dumping syndrome — rapid gastric emptying causing nausea, sweating, and palpitations after eating sugary or high-fat foods

• Post-bariatric hypoglycaemia — a late complication more common after RYGB, caused by exaggerated insulin responses; patients should be aware of symptoms and seek medical review if these occur

• Marginal ulceration at the gastrojejunal anastomosis; patients should avoid NSAIDs and smoking post-operatively, and proton pump inhibitor (PPI) prophylaxis is commonly recommended per local protocols

• Internal herniation, which can occur months to years post-operatively

• Greater risk of nutritional deficiencies, particularly iron, vitamin B12, folate, calcium, and vitamin D, requiring lifelong supplementation

Long-term risks applicable to both procedures include:

• Bone health: Reduced calcium and vitamin D absorption increases the risk of metabolic bone disease and osteoporosis; monitoring and supplementation are essential

• Thiamine (vitamin B1) deficiency: This can occur with persistent vomiting post-operatively and may cause serious neurological complications; urgent medical review is required if prolonged vomiting occurs

Patients should seek urgent medical attention if they experience severe abdominal pain, persistent vomiting, fever, signs of infection, chest pain, or breathlessness following either procedure. The 30-day mortality rate for both operations is low; current UK figures from the NBSR should be consulted for the most up-to-date estimates, as rates vary by centre and patient risk profile. Pre-operative optimisation — including smoking cessation and a liver-reducing diet — is strongly recommended.

Suspected adverse effects or device-related problems should be reported through the MHRA Yellow Card Scheme (available at yellowcard.mhra.gov.uk).

NHS Eligibility Criteria and the Referral Process

NICE CG189 requires a BMI of 35 kg/m² or above with comorbidities, or 40 kg/m² or above without, for NHS bariatric surgery; referral begins with the GP to a Tier 3 specialist weight management service.

Access to bariatric surgery on the NHS is governed by NICE guidance. The primary references are NICE CG189 (Obesity: identification, assessment and management, updated 2022) and NICE NG28 (Type 2 diabetes in adults: management), which together set out eligibility criteria for both general obesity surgery and metabolic surgery for type 2 diabetes.

General eligibility criteria (NICE CG189) include:

• BMI of 35 kg/m² or above with one or more obesity-related comorbidities (e.g., type 2 diabetes, hypertension, obstructive sleep apnoea)

• BMI of 40 kg/m² or above without comorbidities

• For people of South Asian, Chinese, or other high-risk ethnic backgrounds, lower BMI thresholds apply (typically 10 kg/m² lower than standard thresholds)

• Surgery should generally be considered after engagement with appropriate non-surgical weight management interventions, though expedited pathways may apply in certain clinical circumstances

Metabolic surgery for recent-onset type 2 diabetes (NICE NG28):

• Expedited surgical assessment may be considered for adults with a BMI of 30–34.9 kg/m² (or 27.5–32.4 kg/m² for those of Asian family background) with recent-onset type 2 diabetes that is not adequately controlled with optimal medical management

• Patients must demonstrate commitment to long-term follow-up and the ability to comply with post-operative care requirements

The referral pathway typically begins with the patient's GP, who can refer to a Tier 3 specialist weight management service. This multidisciplinary team — comprising dietitians, psychologists, physicians, and surgeons — assesses suitability over several months. Patients are expected to demonstrate engagement with lifestyle modification before surgical referral is progressed.

NHS provision varies by Integrated Care Board (ICB), and waiting times can be lengthy. Some patients choose to pursue surgery privately, in which case the same clinical standards and pre-operative assessments should still apply. Patients considering private surgery should ensure their provider is registered with the Care Quality Commission (CQC) and that surgeons hold appropriate specialist credentials. The British Obesity and Metabolic Surgery Society (BOMSS) provides guidance on standards of care across both NHS and independent sectors.

Recovery, Dietary Changes, and Aftercare Support

Both procedures require a structured dietary progression from liquids to solids over approximately seven weeks, lifelong nutritional supplementation, and regular blood tests, with psychological support integral to long-term success.

Recovery from bariatric surgery requires careful planning and a long-term commitment to dietary and lifestyle change. Both sleeve gastrectomy and Roux-en-Y gastric bypass involve a structured post-operative dietary progression; the specifics vary between procedures and centres, and patients should follow the guidance provided by their own bariatric team.

Typical post-operative dietary stages (UK practice):

• Weeks 1–2: Full liquids, including protein-containing drinks (e.g., milk, protein shakes); clear fluids alone are generally insufficient and not standard UK practice

• Weeks 3–4: Pureed or blended foods

• Weeks 5–6: Soft, moist foods

• Week 7 onwards: Gradual reintroduction of solid foods

Patients are advised to eat small portions slowly, chew thoroughly, avoid drinking fluids with meals, and prioritise protein intake (typically a minimum of 60–80 g per day) to preserve lean muscle mass. High-sugar and high-fat foods should be avoided — particularly after bypass, where they can trigger dumping syndrome. Adequate hydration between meals is important.

Nutritional supplementation is lifelong after both sleeve gastrectomy and gastric bypass, though the specific formulations and doses may differ between procedures and are determined by the treating centre. Standard components typically include:

• A complete multivitamin and mineral supplement

• Vitamin D and calcium

• Iron (particularly important for pre-menopausal women and those at risk of deficiency)

• Vitamin B12 (oral or intramuscular injection, depending on absorption and local protocol)

• Thiamine supplementation should be considered if prolonged vomiting occurs

Regular blood tests are recommended to monitor nutritional status, typically at 3, 6, and 12 months in the first year, then annually thereafter. Tests should include full blood count (FBC), urea and electrolytes (U&Es), liver function tests (LFTs), ferritin, folate, vitamin B12, vitamin D, calcium, and parathyroid hormone (PTH); HbA1c and lipids should be checked as clinically indicated. Patients should follow the monitoring schedule provided by their bariatric team, in line with BOMSS and NICE guidance.

Additional aftercare considerations:

• Pregnancy: Women are advised to avoid conception for at least 12–18 months after surgery, when weight loss is most rapid and nutritional status may be suboptimal. Long-acting reversible contraception (LARC) is preferred after RYGB, as oral contraceptive absorption may be unreliable. Women planning pregnancy after bariatric surgery should seek specialist advice

• Medications: NSAIDs should be avoided after bariatric surgery due to the risk of ulceration, particularly after RYGB. Modified-release and enteric-coated formulations may be poorly absorbed after bypass and should be reviewed by a pharmacist or clinician. Alcohol sensitivity is increased after RYGB, and patients should be counselled accordingly

• Bone health: Adequate calcium and vitamin D supplementation, along with monitoring, is essential to reduce the long-term risk of metabolic bone disease

Psychological support is an integral part of aftercare. Patients may experience significant emotional and behavioural changes following surgery, and access to counselling or support groups can improve long-term outcomes. Most NHS bariatric centres offer structured follow-up for at least two years post-operatively, and patients should be encouraged to remain engaged with their multidisciplinary team throughout.

Choosing the Right Procedure: What the Evidence Says

Gastric bypass is preferred for patients with type 2 diabetes, severe obesity, or significant GORD, while sleeve gastrectomy suits those seeking lower anastomotic risk; the decision should be made collaboratively with a multidisciplinary bariatric team.

Selecting between sleeve gastrectomy and Roux-en-Y gastric bypass is not a straightforward decision, and there is no universally 'correct' answer. The evidence supports an individualised approach, taking into account clinical, psychological, and practical factors. Both procedures require lifelong vitamin and mineral supplementation and long-term follow-up; non-adherence to aftercare is a risk factor for poor outcomes with either operation.

Roux-en-Y gastric bypass may be preferred when:

• The patient has type 2 diabetes and is seeking remission or improved glycaemic control

• Severe obesity (BMI ≥50 kg/m²) is present

• Greater long-term weight loss is a priority

• The patient has significant GORD or Barrett's oesophagus (sleeve gastrectomy may worsen reflux, whereas bypass can improve it in many cases)

Sleeve gastrectomy may be preferred when:

• The patient wishes to avoid the complexity and anastomotic risks of bypass

• The patient has a lower BMI within the surgical range

• Anatomical or surgical factors make bypass technically challenging

• The patient requires chronic anticoagulation or has other factors that increase the risk of anastomotic complications

It is important to note that both procedures require lifelong supplementation; the concern should not be framed as sleeve gastrectomy requiring less commitment to supplementation, but rather that the specific regimens differ. Sleeve gastrectomy can, in some cases, be converted to a gastric bypass at a later date if weight loss is insufficient or if GORD becomes problematic — offering a degree of flexibility in the surgical pathway.

Ultimately, the decision should be made collaboratively between the patient and their multidisciplinary bariatric team, following thorough pre-operative assessment and informed consent, in line with NICE CG189 and BOMSS standards. Patients are encouraged to ask questions, review the available evidence, and consider their own health priorities and lifestyle. Both procedures are effective, evidence-based interventions for obesity and its associated comorbidities, and either can deliver life-changing results when supported by appropriate aftercare and long-term behavioural change.

Frequently Asked Questions